BioNTech files Form 144 to sell 150,000 ADS

BioNTech SE filed a Form 144 notifying of a proposed sale of 150,000 American Depositary Shares on 03/11/2026 for an aggregate offering price of $12,583,500.00 on the Nasdaq Global Select market.

Rhea-AI Filing Summary

BioNTech SE filed a Form 144 notifying of a proposed sale of 150,000 American Depositary Shares on 03/11/2026 for an aggregate offering price of $12,583,500.00 on the Nasdaq Global Select market. The filing lists underlying sources including 95,000 shares from a stock option exercise and 55,000 shares from a private transaction.

Insights

Securities Counsel

Routine Rule 144 notice for resale of ADS tied to prior option exercise and private transfer.

The Form 144 lists 150,000 ADS with an aggregate offering price of $12,583,500.00 and trades to occur on 03/11/2026 on the Nasdaq Global Select. It identifies specific sources: 95,000 from a stock option exercise (11/21/2022) and 55,000 from a private transaction (11/30/2020).

Rule 144 notices are routine administrative disclosures of planned resales; cash‑flow treatment and whether sales are immediate or conditioned are not specified in the excerpt. Subsequent filings or broker notifications would show actual sale execution and price realization.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does BioNTech's (BNTX) Form 144 report?

The Form 144 reports a proposed sale of 150,000 ADS for an aggregate of $12,583,500.00. It lists sources of the shares including 95,000 from an option exercise and 55,000 from a private transaction.

When and where will the securities be sold for BNTX?

The filing sets the proposed sale date as 03/11/2026 on the Nasdaq Global Select. The Form 144 itself does not state execution timing beyond that proposed date or confirm completed trades.

Are the shares listed in the Form 144 registered or restricted for BNTX?

The Form 144 is a notice of proposed resale under Rule 144 and identifies the ADS and their sources. It does not by itself convert restricted shares to registered shares; trading depends on satisfying Rule 144 conditions.

What are the sources of the 150,000 ADS in the filing?

The filing identifies 95,000 ADS from a stock option exercise dated 11/21/2022 and 55,000 ADS from a private transaction dated 11/30/2020. Those line items are shown in the excerpt.

Does this Form 144 indicate proceeds go to BioNTech (BNTX)?

The Form 144 lists the proposed sale of ADS by a holder; it does not state that proceeds will be received by BioNTech. The excerpt does not specify the cash‑flow recipient.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/11/2026 - 08:02 AM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001955589
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	BioNTech SE
SEC File Number	001-39081
Address of Issuer	AN DER GOLDGRUBE 12 MAINZ GERMANY 55131
Phone	0049613190840
Name of Person for Whose Account the Securities are To Be Sold	Poetting Sierk
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares representing ordinary shares, no par value per share	Berenberg Capital Markets LLC 1251 Avenue of the Americas 53rd Floor New York NY 10020	150000	12583500.00	239970804	03/11/2026	Nasdaq Global Select

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary Shares, no par value per share	11/21/2022	Stock Option Exercise	BioNTech SE			95000	11/21/2022	Stock Option Exercise
Ordinary Shares, no par value per share	09/09/2016	Private Transaction	Medine GmbH			55000	11/30/2020	Cash (1)

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The filing of this Form 144 shall not be construed as an admission that the undersigned is an affiliate of the issuer. (1) Payment for securities made in two installments in November 2020, with the final payment made on November 30, 2020.
Date of Notice	03/11/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Sierk Poetting
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)